Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor, In Vivo
UK
11+ years of experience
In Vivo
By Lucie Ellis 27 Nov 2020
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Topic Coronavirus Vaccines
In Vivo
By Lucie Ellis 06 Mar 2020
The coronavirus outbreak is at a tipping point, after which its development into a global pandemic may be unstoppable. Companies large and small have mobilized in the fight against the disease bringing new and repurposed treatment options into development and preparing their business for the unsteady months ahead.
Topic Coronavirus
In Vivo
By Lucie Ellis 02 Jul 2019
With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies.
Topic BioPharmaceutical Approvals Drug Development Landscape Drug Review
Scrip
By Lucie Ellis 11 Jun 2019
Potential upheavals in the hemophilia market bring uncertainty for Shire and Bayer, with executives likely to be quizzed on how they can retain market share during upcoming Q4 results calls. Scrip’s final earnings preview highlights the key challenges for large companies reporting at the tail-end of the earnings season.
In Vivo
By Lucie Ellis 10 Jun 2019
As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.
In Vivo
By Lucie Ellis 22 Aug 2018
Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.
In Vivo
By Lucie Ellis 17 Aug 2018
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
Topic Approvals Drug Review
Scrip
By Lucie Ellis 24 Apr 2018
Scrip investigates the big issues Israel's biopharma sector need to overcome in order to maintain momentum and achieve sustainable success.
Topic BioPharmaceutical
Scrip
By Lucie Ellis 23 Feb 2018
As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.
Topic Business Strategies
Scrip
By Lucie Ellis 21 Feb 2018
In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.
Topic Cancer
Scrip
By Lucie Ellis 22 Dec 2017
Ray Barlow talks to Scrip on the sidelines of the BIO-Europe partnering conference in Berlin.
Scrip
By Lucie Ellis 17 Oct 2017
Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product
Scrip
By Lucie Ellis 03 Oct 2017
With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy
Topic Rare Diseases
Scrip
By Lucie Ellis 22 Sep 2017
Oxford, UK-based Immunocore, which is developing immunotherapies against cancer
Topic Cancer
Scrip
By Lucie Ellis 26 Jul 2017
Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.
Topic Cancer immuno-oncology Research & Development Strategy
In Vivo
04 Nov 2021
In Vivo
14 Oct 2021
Medtech Insight
14 Oct 2021
Medtech Insight
29 Sep 2021
In Vivo
13 Sep 2021
In Vivo
16 Aug 2021
In Vivo
14 Jul 2021
In Vivo
14 Jul 2021
In Vivo
13 Jul 2021
In Vivo
19 May 2021
In Vivo
19 Apr 2021
In Vivo
07 Apr 2021
Scrip
18 Sep 2017
Scrip
14 Sep 2017
Scrip
05 Sep 2017
